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Objective
AIDS-associated Kaposi's sarcoma (KS) is a common
malignancy in regions with high HIV and Kaposi's Sar-
coma-Associated Virus (KSHV) co-infection. This is exac-
erbated by limited access to antiretroviral therapy. Despite
the dramatic increase in HIV in South Africa since the
mid-1990s, little is known about the rates of AIDS-associ-
ated KS. Our objective is to estimate trends in the inci-





The incidence of KS (per 100,000) was estimated using
anonymous administrative records for patients receiving
care for KS through all public sector oncology clinics in
KwaZulu-Natal, 1983 to 2006. Age-standardized inci-
dence rates were calculated annually using provincial cen-
sus data for the black population from 1985, 1996, 2001
and 2005. Age-specific rates were calculated for 1983–
1989 (baseline) and for 2006 (generalized HIV epi-
demic).
Results
The age-standardized incidence of KS continues to
increase in KwaZulu-Natal. Between 1983 and 2006, age-
standardized incidence rates in men increased from 1.04
to 19.7 cases per 100,000, while in women they increased
50-fold, from 0.21 to 11.51 cases per 100,000. Overall,
incidence has increased from 0.52 to 14.76 cases per
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100,000 (Figure 1). This pattern of increase mirrors that of
the HIV antenatal clinic seroprevalence for Kwazulu-
Natal, which increased steadily from 1.6 percent in 1989
to 39 percent in 2006. In 2006, peak age-specific inci-
dence in men is 63.1 cases per 100,000 and in women is
43.5 cases per 100,000 (Figure 2), with peaks shifting to
the fourth and fifth decades of life, compared to a peak
incidence between ages 55–60 in the pre-HIV era (1983–
1989). During the last decade, the mean male:female ratio
was 2.3.
Conclusion
Our estimates of KS incidence are based only on those
who are referred to public sector oncologists, and exclude
both early and late stage KS that would be treated by pri-
mary care providers or hospice, as well as those treated in
the private sector. We therefore greatly underestimate the
true incidence AIDS-associated KS in the province, and
absolute rates cannot be compared directly to cancer-reg-
istry data from other African countries. Nonetheless, we
demonstrate that the incidence of AIDS-associated KS
continues to increase through 2006, and is a growing pub-
lic health problem in KwaZulu-Natal, South Africa.
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